Summary of the impact

Research undertaken at the Centre for Intellectual and Developmental Disabilities(CIDD), has significantly impacted upon:

1. The identification of health inequalities through improved health surveillance.
2. The development of a network of Health Facilitators linked to GP Practices to promote health screening/annual checks.
3. The development of accessible information to assist people with ID in making positive lifestyle choices and access healthcare services.
4. The development of health promotion interventions targeting secondary health conditions for people with ID.
5. The translation of this research into pre/post multi-disciplinary education.
6. The preparation of regional, national and international policy guidelines.

Summary of the impact

Our research showed that powered rotation oscillation toothbrushes were superior to manual toothbrushes for the removal of plaque and reduction of gingivitis. This information has had impacts on national public policy, on commerce and on society.

1. The findings were used by the Department of Health in its evidence-based guidelines for preventing oral disease, which is NHS policy on preventive dentistry in England and Wales.
2. The research has also been used in worldwide marketing by Procter and Gamble (the manufacturers of the leading brand of powered rotation-oscillation toothbrush), and by another manufacturer as part of its marketing strategy for a new toothbrush.
3. Finally, as a result of this work there have been critical reviews of the research and of the toothbrushes in the media that have enabled more informed consumer choice for oral hygiene.

Summary of the impact

Starting from a mechanism-based hypothesis, Alastair Compston and colleagues in Cambridge have led the academic development of Alemtuzumab as a highly effective therapy for relapsing-remitting multiple sclerosis through Phase 1, 2 and two Phase 3 trials (1991-2012). The impacts to date are demonstration of the importance of the therapeutic `window of opportunity' in treating multiple sclerosis; a product licence in the European Union (September 2013) for the commonest potentially disabling neurological disease of young adults; expansion of the work-force in industry to develop and market this initiative; and an estimated several-fold increase in revenue to the University of Cambridge (and other beneficiaries) from total royalties of £18.6M from 1997 to date.

Summary of the impact

In 2007, as part of a major update of the national alcohol strategy, the UK Government announced that it would commission an independent national review of the evidence on the relationship between alcohol price, promotion and harm. Subsequently, in 2008, researchers from the University of Sheffield (UoS) were commissioned by the UK Department of Health (DoH) for an `Independent Review of the Effects of Alcohol Pricing and Promotion'.

The UoS research has played a crucial role in informing the debate and deliberations on the available Government options for interventions on alcohol consumption in England and Wales, by providing a robust evidence base to underpin the debate. The UoS research findings have been used to inform policy by senior decision-making bodies e.g. the House of Commons Health Select Committee and the UK Chief Medical Officer to inform policy. The findings have also stimulated the potential for policy intervention beyond England and Wales, e.g. in Scotland and Australia.

Summary of the impact

Alternatives to acute admission in mental health are crucial, not least because of the high cost of inpatient care. We have carried out a major research programme that includes the only randomised controlled evaluation of crisis resolution teams and the only major UK study of crisis houses, which are community-based, residential alternatives to hospital admission. This programme demonstrated the efficacy of community treatment and has significantly influenced decision making at a local and national policy level, including commissioning guidance and three sets of NICE guidelines. This has contributed to changes in the way acute services for severely mentally ill adults are configured in the NHS, and internationally.

Summary of the impact

Our research on alternatives to medication in the treatment of childhood epilepsy has resulted in increasing rates of surgery with better outcomes, and a new clinical service — the national Children's Epilepsy Surgery Service (CESS) — being commissioned in England and Wales. We have also developed an evidence base for ketogenic dietary therapy, resulting in an increase in service provision. Many more patients are benefiting from this therapy, which is now recommended in NICE guidelines. Throughout our programme of research we have engaged with charities and patient groups to disseminate the results of our research as widely as possible.

Summary of the impact

Abdominal aortic aneurysm (AAA) is a major cause of death in older men, in the UK and elsewhere. A large UK trial led by the University of Cambridge evaluated the long-term benefits of ultrasound screening for AAA in men aged 65-74 years. This provided the basis for the introduction of a UK national AAA screening programme in men aged 65; this was announced in 2008, initiated in 2009, and achieved full coverage of England in 2013. Similar screening has started in Sweden, New Zealand and in parts of Italy, and is being actively discussed in Denmark, Norway and Finland.

Summary of the impact

As a result of University of Sheffield research in 1995-2002, a new gold standard treatment for major bleeding on warfarin has been established, ensuring the more effective treatment of tens of thousands of patients requiring emergency anticoagulation reversal each year in the UK alone. The treatment, using prothrombin complex concentrate (PCC) was demonstrated to be superior to fresh frozen plasma (FFP), the standard alternative at the time, and two PCCs have now been licensed for this indication in the UK.

UK and international guidelines now recommend PCC over FFP.

Summary of the impact

The decision about whether to fund new health care interventions is increasingly being informed by evidence of cost-effectiveness in terms of the cost per Quality Adjusted Life Years (QALY). The SF-6D health index is widely used internationally for calculating QALYs from patient reported health outcomes collected in clinical trials and other surveys. It contributes to health system efficiency from being used by health technology agencies around the world (including Australia, Canada, England, Scotland, Ireland and Norway) to calculate QALYs to facilitate decisions about the most efficient use of limited health care resources. The SF-6D is freely available to non-commercial bodies, including researchers and policy makers. Commercial benefits come from the licensing of the measure to pharmaceutical companies, health insurers and others to assess the cost-effectiveness of their products with 460 licenses being sold since 2008. A further 521 licenses are distributed on a non-commercial basis to academic researchers, public sector and charitable organisations.

Summary of the impact

Research led by Dr Holmes has identified a novel variant of methicillin-resistant Staphylococcus aureus (MRSA) in livestock. This represents a previously unidentified reservoir of infection which has had impact on the epidemiology of MRSA and its management. This research also impacts on antibiotic use in agriculture and its role in the emergence of antibiotic resistance. As a consequence of these research findings commercial tests and testing protocols have been developed to detect the new MRSA variant, which are now used widely in clinical settings throughout Europe. The discovery has also been used to inform policy decisions at a governmental level in the USA and Europe.